The current pandemic of multiple variants has created an urgent need for effective inhibitors of SARS-CoV-2 to complement vaccine strategies. PF-07321332, developed by Pfizer, is the first orally administered coronavirus-specific main protease inhibitor approved by the FDA.

Cats are the definitive hosts of Toxoplasma gondii. The distribution of genetic diversity of T. gondii in cats is of importance to understand the transmission of this parasite. The objective of this study was to genetically characterize T. gondii isolates from cats in Yunnan province, southwestern China. Genomic DNA was extracted from 5–10 g cat tissue samples (brain, tongue, heart, and liver). Using multilocous polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technology, we determined genetic diversity of T. gondii isolates from cats in Yunnan province. In total, 175 stray cats were tested for T. gondii DNA, respectively, 44 (25.14%) of which were found to be positive for the T. gondii B1 gene by PCR amplification. The positive DNA samples were typed at 11 genetic markers, including 10 nuclear markers, namely, SAG1, 5'-3' SAG2, alternative SAG2, SAG3, GRA6, L358, PK1, BTUB, c22-8, c29-2 and an apicoplast locus Apico. Of these, 16 isolates from cats were genotyped with data for more than 9 loci, revealed 5 genotypes in total, of which 11 of 16 samples were identified as ToxoDB#9, two samples may belong to genotye #225, one was Type II, one was ToxoDB#3, and one was ToxoDB#20 ( http://toxodb.org/toxo/ ). The results of the present study indicated a wide distribution of T. gondii infection in cats in Yunnan province, which may pose significant public health concerns. To our knowledge, the present study is the first report of T. gondii prevalence and genotypes in cats in southwestern China, and the first report of Type II T. gondii from cats in China.

Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), the pathogen of the Coronavirus disease-19 (COVID-19), is still devastating the world causing significant chaos to the international community and posing a significant threat to global health. Since the first outbreak in late 2019, several lines of intervention have been developed to prevent the spread of this virus. Nowadays, some vaccines have been approved and extensively administered. However, the fact that SARS-CoV-2 rapidly mutates makes the efficacy and safety of this approach constantly under debate. Therefore, antivirals are still needed to combat the infection of SARS-CoV-2. Papain-like protease (PLpro) of SARS-CoV-2 supports viral reproduction and suppresses the innate immune response of the host, which makes PLpro an attractive pharmaceutical target. Inhibition of PLpro could not only prevent viral replication but also restore the antiviral immunity of the host, resulting in the speedy recovery of the patient. In this review, we describe structural and functional features on PLpro of SARS-CoV-2 and the latest development in searching for PLpro inhibitors. Currently available inhibitors targeting PLpro as well as their structural basis are also summarized.